A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers
FFCD-2205
2 other identifiers
observational
150
1 country
40
Brief Summary
The aim of this French multicenter retrospective study is to describ rare primary hepatic cancers clinical, histological and radiological features, to obtain a biological tumor and blood collection, and to evaluate the efficacy of treatments received in clinical practice in order to determine optimal therapeutic sequences. This retrospective cohort will be the backbone of future translational studies aimed at identifying new molecular, histological, circulating and radiological tumor biomarkers, potentially useful at every stage of diagnosis and prognostic or theranostic evaluation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Mar 2024
Longer than P75 for all trials
40 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 26, 2024
CompletedFirst Submitted
Initial submission to the registry
July 15, 2024
CompletedFirst Posted
Study publicly available on registry
August 7, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2031
ExpectedAugust 5, 2025
February 1, 2025
1.9 years
July 15, 2024
August 4, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
Description of the clinical, histological and radiological characteristics of various rare primary liver cancers
up to 5 years from the date of diagnosis
Secondary Outcomes (3)
Recurrence-free survival (for non-metastatic patients)
up to 5 years from diagnosis
Progression-free survival (for metastatic patients)
up to 5 years from diagnosis
Overall survival
up to 5 years from diagnosis
Eligibility Criteria
In the health centers, patients were identified in two ways: 1. via diagnoses obtained in the anatomopathology departments of each investigating center 2. via multidisciplinary consultation meetings on primary hepatic tumours/digestive oncology at each investigating center. Patients with a diagnosis of rare primary hepatic cancers diagnosed on or after 01/01/2018 may be included, whether alive or deceased at the time of registration in the CAPRIH cohort.
You may qualify if:
- years of age or older,
- with histologically proven hepato-cholangiocarcinoma, fibrolamellar hepatocellular carcinoma, epithelioid hemangioendothelioma or hepatic angiosarcoma
- diagnosed after January 01, 2018 living or deceased at the time of registration in the cohort
- for living patients who have not objected to the research: (note of non-objection to be attached° agreeing to participate in ancillary studies must sign the biological consent form for participation in biological studies.
You may not qualify if:
- without social security
- No access to tumor block
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (40)
CHU Amiens picardie
Amiens, 80054, France
Chu Angers
Angers, 49933, France
Ch - Centresimone Veil de Beauvais
Beauvais, 60021, France
Chu Jean Minjoz
Besançon, France
Ch Bethune Beuvry
Béthune, 62408, France
Avicenne
Bobigny, 93000, France
Cote de Nacre
Caen, France
Centre Hospitalier
Calais, France
Chu de Clichy Hopital Beaujon
Clichy, 92110, France
Centre Hospitalier Universitaire Henri Mondor
Créteil, 94010, France
CHU
Dijon, 21079, France
Chu Grenobles Alpes
La Tronche, 38700, France
Centre Hospital Universitaire de lille
Lille, 59000, France
Longjumeau Ch Nord Essone
Longjumeau, France
Ch Edouard Herriot
Lyon, 69002, France
Centre Léon Berard
Lyon, 69008, France
La Clinique de La Sauvegarde
Lyon, 69009, France
Chu Edouard Herriot
Lyon, France
Lyon Cac Leon Berard
Lyon, France
Lyon La Croix Rousse
Lyon, France
Hopital Saint Joseph
Marseille, 13285, France
Chu de La Timone
Marseille, 13385, France
CHR - Metz Thionville Hopital de Mercy
Metz, 57085, France
CHU La Source
Orléans, France
Chu de Paris Saint Antoine
Paris, 75571, France
AP - HP - Pitié Salpêtrière
Paris, 75651, France
PAU CH
Pau, 64000, France
Centre Hospitalier de Perpignan
Perpignan, 66046, France
Hopital Haut Leveque
Pessac, 33604, France
Chu de Poitiers
Poitiers, 86021, France
CH - Annecy Genevois
Pringy, 74374, France
Chu Robert Debre
Reims, 51000, France
CAC - Eugène Marquis
Rennes, 35042, France
Ico Site Rene Gauducheau
Saint-Herblain, 44805, France
Hopital Nord Chu Saint Etienne
Saint-Priest-en-Jarez, France
Groupe Hospitalier Rance Emeraude
St-Malo, 35403, France
Chu Rangueil
Toulouse, France
Chru de Tours
Tours, 37044, France
Chu Paul Brousse
Villejuif, France
Gustave Roussy
Villejuif, France
Biospecimen
A research blood sample, taken as part of a blood test carried out as part of the patient's care, for living patients with active cancer at the time of registration. If possible, the sample should be taken before a new cancer treatment is carried out. The volume of blood collected will be: 2 x 8.5 mL cell free DNA tubes to collect circulating tumor DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
jean-charles nault, Pr
Federation Francophone de Cancerologie Digestive
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 15, 2024
First Posted
August 7, 2024
Study Start
March 26, 2024
Primary Completion
February 1, 2026
Study Completion (Estimated)
February 1, 2031
Last Updated
August 5, 2025
Record last verified: 2025-02
Data Sharing
- IPD Sharing
- Will not share